Form ADV disclosures
Healthcare and life sciences investment advisers face a specific disclosure burden under Form ADV that most pure-play financial firms do not: the U.S. Securities and Exchange Commission has signaled, through its 2023 Marketing Rule examination priorities and its Staff Risk Alert on adviser due diligence practices, that healthcare-focused advisers must document material conflicts arising from portfolio company clinical relationships, licensing dependencies, and government reimbursement exposure. The Financial Industry Regulatory Authority applies parallel scrutiny where dual-registered entities are involved. Compliance teams at life sciences advisers are currently reconciling Part 2A narrative disclosures against updated conflict-of-interest inventories before their next annual amendment cycle.
Watch
- SEC Staff Risk Alert on investment adviser due diligence: conflicts documentation scope
- Form ADV Part 2A annual amendment deadline: 90-day post-fiscal-year filing window
- FINRA Rule 2210 intersection for dual-registered advisers with healthcare fund marketing materials
- Reimbursement-tied portfolio company relationships: SEC examination focus on undisclosed revenue dependencies
Recent material activity in Healthcare & Life Sciences
-
FDA issues Complete Response Letter for novel GLP-1 receptor agonist oral formulation
The FDA issued a CRL for a once-daily oral GLP-1 receptor agonist citing manufacturing consistency concerns at the primary production facility. The agency requested additional CMC data and a pre-approval inspection befor…
Read a full sample brief →